Total revenue of $230.2 million grew 25% year-over-year and annual revenue exceeded previously-established outlook Net loss and Adjusted EBITDA1 improved to ($32.5) million and $4.4 million, respectively GPV as a percentage of GTV was 32% in the quarter, up from 19% in the prior year ARPU2 of ~$431 grew 29% year-over-year with Net Retention Rate of ~110% Lightspeed reports in US dollars and in accordance with IFRS.

TORONTO, May 16, 2024 /CNW/ - Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) (the "Company" or "Arizona Metals") is delighted to announce key changes in its leadership team to steer the Company into its next phase of growth. To facilitate the progression of Arizona Metals, Marc Pais (CEO) and Paul Reid (Executive Chair) made the decision to initiate an extensive search process for an experienced mine development leadership team.

Company continues to advance its corticosteroid production platform and anticipates signing a large strategic partnership in Q2 2024 Signed two new program agreements, and advanced three programs to the next phase of development toward commercialization Willow reiterates its expectations of at least doubling its full year 2024 revenues SUNNYVALE, Calif., May 13, 2024 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further ...

Completes Major Steps Towards Profitability with Best Revenue and Adjusted EBITDA in Over Three Years TORONTO, May 15, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three months ended March 31, 2024.